Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Extracellular vesicle fibrinogen induces encephalitogenic CD8+ T cells in a mouse model of multiple sclerosis.

Willis CM, Nicaise AM, Menoret A, Ryu JK, Mendiola AS, Jellison ER, Givogri MI, Han DK, Bongarzone ER, Akassoglou K, Vella AT, Crocker SJ.

Proc Natl Acad Sci U S A. 2019 May 21;116(21):10488-10493. doi: 10.1073/pnas.1816911116. Epub 2019 May 8.

2.

Long Noncoding RNAs in Host-Pathogen Interactions.

Agliano F, Rathinam VA, Medvedev AE, Vanaja SK, Vella AT.

Trends Immunol. 2019 Jun;40(6):492-510. doi: 10.1016/j.it.2019.04.001. Epub 2019 Apr 30. Review.

PMID:
31053495
3.

Costimulation Induces CD4 T Cell Antitumor Immunity via an Innate-like Mechanism.

Morales Del Valle C, Maxwell JR, Xu MM, Menoret A, Mittal P, Tsurutani N, Adler AJ, Vella AT.

Cell Rep. 2019 Apr 30;27(5):1434-1445.e3. doi: 10.1016/j.celrep.2019.04.016.

4.

Single cell transcriptomics based-MacSpectrum reveals novel macrophage activation signatures in diseases.

Li C, Menoret A, Farragher C, Ouyang Z, Bonin C, Holvoet P, Vella AT, Zhou B.

JCI Insight. 2019 Apr 16;5. pii: 126453. doi: 10.1172/jci.insight.126453.

5.

Direct CD137 costimulation of CD8 T cells promotes retention and innate-like function within nascent atherogenic foci.

Xu MM, Ménoret A, Nicholas SE, Günther S, Sundberg EJ, Zhou B, Rodriguez A, Murphy PA, Vella AT.

Am J Physiol Heart Circ Physiol. 2019 Jun 1;316(6):H1480-H1494. doi: 10.1152/ajpheart.00088.2019. Epub 2019 Apr 12.

PMID:
30978132
6.

Activated T-effector seeds: cultivating atherosclerotic plaque through alternative activation.

Xu MM, Murphy PA, Vella AT.

Am J Physiol Heart Circ Physiol. 2019 Jun 1;316(6):H1354-H1365. doi: 10.1152/ajpheart.00148.2019. Epub 2019 Mar 29.

PMID:
30925075
7.

Block of Granulocyte-Macrophage Colony-Stimulating Factor Prevents Inflammation-Induced Preterm Birth in a Mouse Model for Parturition.

Nold C, Stone J, O'Hara K, Davis P, Kiveliyk V, Blanchard V, Yellon SM, Vella AT.

Reprod Sci. 2019 Apr;26(4):551-559. doi: 10.1177/1933719118804420. Epub 2018 Oct 8.

PMID:
30296925
8.

Gasdermin D Restrains Type I Interferon Response to Cytosolic DNA by Disrupting Ionic Homeostasis.

Banerjee I, Behl B, Mendonca M, Shrivastava G, Russo AJ, Menoret A, Ghosh A, Vella AT, Vanaja SK, Sarkar SN, Fitzgerald KA, Rathinam VAK.

Immunity. 2018 Sep 18;49(3):413-426.e5. doi: 10.1016/j.immuni.2018.07.006. Epub 2018 Aug 28.

PMID:
30170814
9.

Understanding how combinatorial targeting of TLRs and TNFR family costimulatory members promote enhanced T cell responses.

Shinde P, Bharat V, Rodriguez-Oquendo A, Zhou B, Vella AT.

Expert Opin Biol Ther. 2018 Oct;18(10):1073-1083. doi: 10.1080/14712598.2018.1518422. Epub 2018 Sep 12. Review.

PMID:
30169979
10.

T cell-directed IL-17 production by lung granular γδ T cells is coordinated by a novel IL-2 and IL-1β circuit.

Ménoret A, Buturla JA, Xu MM, Svedova J, Kumar S, Rathinam VAK, Vella AT.

Mucosal Immunol. 2018 Sep;11(5):1398-1407. doi: 10.1038/s41385-018-0037-0. Epub 2018 Jun 15.

PMID:
29907868
11.

A novel biologic platform elicits profound T cell costimulatory activity and antitumor immunity in mice.

Ryan JM, Mittal P, Menoret A, Svedova J, Wasser JS, Adler AJ, Vella AT.

Cancer Immunol Immunother. 2018 Apr;67(4):605-613. doi: 10.1007/s00262-018-2116-1. Epub 2018 Jan 11.

12.

An Immunotherapeutic CD137 Agonist Releases Eomesodermin from ThPOK Repression in CD4 T Cells.

Mittal P, Abblett R, Ryan JM, Hagymasi AT, Agyekum-Yamoah A, Svedova J, Reiner SL, St Rose MC, Hanley MP, Vella AT, Adler AJ.

J Immunol. 2018 Feb 15;200(4):1513-1526. doi: 10.4049/jimmunol.1701039. Epub 2018 Jan 5.

13.

Macrophage polarization and meta-inflammation.

Li C, Xu MM, Wang K, Adler AJ, Vella AT, Zhou B.

Transl Res. 2018 Jan;191:29-44. doi: 10.1016/j.trsl.2017.10.004. Epub 2017 Nov 3. Review.

14.

Programmed cell death-1, PD-1, is dysregulated in T cells from children with new onset type 1 diabetes.

Granados HM, Draghi A 2nd, Tsurutani N, Wright K, Fernandez ML, Sylvester FA, Vella AT.

PLoS One. 2017 Sep 6;12(9):e0183887. doi: 10.1371/journal.pone.0183887. eCollection 2017.

15.

A Refined Bead-Free Method to Identify Astrocytic Exosomes in Primary Glial Cultures and Blood Plasma.

Willis CM, Ménoret A, Jellison ER, Nicaise AM, Vella AT, Crocker SJ.

Front Neurosci. 2017 Jun 15;11:335. doi: 10.3389/fnins.2017.00335. eCollection 2017.

16.

Addressing current challenges in cancer immunotherapy with mathematical and computational modelling.

Konstorum A, Vella AT, Adler AJ, Laubenbacher RC.

J R Soc Interface. 2017 Jun;14(131). pii: 20170150. doi: 10.1098/rsif.2017.0150. Review.

17.

IRF6 Regulates Alternative Activation by Suppressing PPARγ in Male Murine Macrophages.

Li C, Ying W, Huang Z, Brehm T, Morin A, Vella AT, Zhou B.

Endocrinology. 2017 Sep 1;158(9):2837-2847. doi: 10.1210/en.2017-00053.

18.

Therapeutic blockade of CD54 attenuates pulmonary barrier damage in T cell-induced acute lung injury.

Svedova J, Ménoret A, Mittal P, Ryan JM, Buturla JA, Vella AT.

Am J Physiol Lung Cell Mol Physiol. 2017 Jul 1;313(1):L177-L191. doi: 10.1152/ajplung.00050.2017. Epub 2017 May 4.

19.

Optimal CD4 T cell priming after LPS-based adjuvanticity with CD134 costimulation relies on CXCL9 production.

Shinde P, Liu W, Ménoret A, Luster AD, Vella AT.

J Leukoc Biol. 2017 Jul;102(1):57-69. doi: 10.1189/jlb.1A0616-261RR. Epub 2017 Apr 21.

20.

Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy.

Adler AJ, Mittal P, Ryan JM, Zhou B, Wasser JS, Vella AT.

Immunotherapy. 2017 Jan;9(1):71-82. doi: 10.2217/imt-2016-0097. Review.

21.

Lymphocyte activation gene 3 and coronary artery disease.

Golden D, Kolmakova A, Sura S, Vella AT, Manichaikul A, Wang XQ, Bielinski SJ, Taylor KD, Chen YI, Rich SS, Rodriguez A.

JCI Insight. 2016 Oct 20;1(17):e88628. doi: 10.1172/jci.insight.88628.

22.

Regulatory T Cells and Cancer: A Two-Sided Story.

Wang K, Vella AT.

Immunol Invest. 2016 Nov;45(8):797-812. Epub 2016 Sep 7. Review.

PMID:
27603750
23.

Characterizing the inflammatory response in esophageal mucosal biopsies in children with eosinophilic esophagitis.

Sayej WN, Ménoret A, Maharjan AS, Fernandez M, Wang Z, Balarezo F, Hyams JS, Sylvester FA, Vella AT.

Clin Transl Immunology. 2016 Jul 1;5(7):e88. doi: 10.1038/cti.2016.30. eCollection 2016 Jul.

24.

TNF and CD28 Signaling Play Unique but Complementary Roles in the Systemic Recruitment of Innate Immune Cells after Staphylococcus aureus Enterotoxin A Inhalation.

Svedova J, Tsurutani N, Liu W, Khanna KM, Vella AT.

J Immunol. 2016 Jun 1;196(11):4510-21. doi: 10.4049/jimmunol.1600113. Epub 2016 Apr 20.

25.

Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?

Ryan JM, Wasser JS, Adler AJ, Vella AT.

Expert Opin Biol Ther. 2016;16(5):655-74. doi: 10.1517/14712598.2016.1152256. Epub 2016 Feb 25. Review.

26.

Costimulation Endows Immunotherapeutic CD8 T Cells with IL-36 Responsiveness during Aerobic Glycolysis.

Tsurutani N, Mittal P, St Rose MC, Ngoi SM, Svedova J, Menoret A, Treadway FB, Laubenbacher R, Suárez-Ramírez JE, Cauley LS, Adler AJ, Vella AT.

J Immunol. 2016 Jan 1;196(1):124-34. doi: 10.4049/jimmunol.1501217. Epub 2015 Nov 16.

27.

Tumor-Unrelated CD4 T Cell Help Augments CD134 plus CD137 Dual Costimulation Tumor Therapy.

Mittal P, St Rose MC, Wang X, Ryan JM, Wasser JS, Vella AT, Adler AJ.

J Immunol. 2015 Dec 15;195(12):5816-26. doi: 10.4049/jimmunol.1502032. Epub 2015 Nov 11.

28.

Trace Levels of Staphylococcal Enterotoxin Bioactivity Are Concealed in a Mucosal Niche during Pulmonary Inflammation.

Ménoret A, Svedova J, Behl B, Vella AT.

PLoS One. 2015 Oct 28;10(10):e0141548. doi: 10.1371/journal.pone.0141548. eCollection 2015.

29.

Transition from identity to bioactivity-guided proteomics for biomarker discovery with focus on the PF2D platform.

Ménoret A, Crocker SJ, Rodriguez A, Rathinam VA, Clark RB, Vella AT.

Proteomics Clin Appl. 2016 Jan;10(1):8-24. doi: 10.1002/prca.201500029. Epub 2015 Sep 16. Review.

PMID:
26201056
30.

Responses to LPS boost effector CD8 T-cell accumulation outside of signals 1 and 2.

Liu W, Menoret A, Vella AT.

Cell Mol Immunol. 2017 Mar;14(3):254-253. doi: 10.1038/cmi.2015.69. Epub 2015 Jul 20.

31.
32.

The role of PGE2 in intestinal inflammation and tumorigenesis.

Montrose DC, Nakanishi M, Murphy RC, Zarini S, McAleer JP, Vella AT, Rosenberg DW.

Prostaglandins Other Lipid Mediat. 2015 Jan-Mar;116-117:26-36. doi: 10.1016/j.prostaglandins.2014.10.002. Epub 2014 Oct 22.

33.

Therapeutic targeting of the inflammome.

Wright KT, Giardina C, Vella AT.

Biochem Pharmacol. 2014 Nov 15;92(2):184-91. doi: 10.1016/j.bcp.2014.08.027. Epub 2014 Sep 6. Review.

34.

Distinctive colonic mucosal cytokine signature in new-onset, untreated pediatric Crohn disease.

Sylvester FA, Draghi A, Menoret A, Fernandez ML, Wang Z, Vella AT.

J Pediatr Gastroenterol Nutr. 2014 Nov;59(5):553-61. doi: 10.1097/MPG.0000000000000480.

PMID:
25000355
35.

Striving for synergy: how to improve cancer immunotherapy through multiple agonist costimulation.

Adler AJ, Vella AT.

Immunotherapy. 2013 Dec;5(12):1271-3. doi: 10.2217/imt.13.129. No abstract available.

PMID:
24283834
36.

Baseline serum C-reactive protein and death from colorectal cancer in the NHANES III cohort.

Swede H, Hajduk AM, Sharma J, Rawal S, Rasool H, Vella AT, Tobet RE, Stevens RG.

Int J Cancer. 2014 Apr 15;134(8):1862-70. doi: 10.1002/ijc.28504. Epub 2013 Oct 31.

37.

RKIP contributes to IFN-γ synthesis by CD8+ T cells after serial TCR triggering in systemic inflammatory response syndrome.

Wright KT, Vella AT.

J Immunol. 2013 Jul 15;191(2):708-16. doi: 10.4049/jimmunol.1203486. Epub 2013 Jun 12.

38.
39.

Rapid αβ T-cell responses orchestrate innate immunity in response to Staphylococcal enterotoxin A.

Kumar S, Colpitts SL, Ménoret A, Budelsky AL, Lefrancois L, Vella AT.

Mucosal Immunol. 2013 Sep;6(5):1006-15. doi: 10.1038/mi.2012.138. Epub 2013 Jan 16.

40.

CD134/CD137 dual costimulation-elicited IFN-γ maximizes effector T-cell function but limits Treg expansion.

St Rose MC, Taylor RA, Bandyopadhyay S, Qui HZ, Hagymasi AT, Vella AT, Adler AJ.

Immunol Cell Biol. 2013 Feb;91(2):173-83. doi: 10.1038/icb.2012.74. Epub 2013 Jan 8.

41.

Differential proteomics identifies PDIA3 as a novel chemoprevention target in human colon cancer cells.

Ménoret A, Drew DA, Miyamoto S, Nakanishi M, Vella AT, Rosenberg DW.

Mol Carcinog. 2014 Feb;53 Suppl 1:E11-22. doi: 10.1002/mc.21986. Epub 2012 Dec 19.

PMID:
23255428
42.

Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells.

Tewalt EF, Cohen JN, Rouhani SJ, Guidi CJ, Qiao H, Fahl SP, Conaway MR, Bender TP, Tung KS, Vella AT, Adler AJ, Chen L, Engelhard VH.

Blood. 2012 Dec 6;120(24):4772-82. doi: 10.1182/blood-2012-04-427013. Epub 2012 Sep 19.

43.

Cytochrome b5 and cytokeratin 17 are biomarkers in bronchoalveolar fluid signifying onset of acute lung injury.

Ménoret A, Kumar S, Vella AT.

PLoS One. 2012;7(7):e40184. doi: 10.1371/journal.pone.0040184. Epub 2012 Jul 6.

44.

Presensitizing with a Toll-like receptor 3 ligand impairs CD8 T-cell effector differentiation and IL-33 responsiveness.

Ngoi SM, St Rose MC, Menoret AM, Smith DE, Tovey MG, Adler AJ, Vella AT.

Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):10486-91. doi: 10.1073/pnas.1202607109. Epub 2012 Jun 11.

45.

Acute sensitization of colon cancer cells to inflammatory cytokines by prophase arrest.

Kuratnik A, Senapati VE, Verma R, Mellone BG, Vella AT, Giardina C.

Biochem Pharmacol. 2012 May 1;83(9):1217-28. doi: 10.1016/j.bcp.2012.01.024. Epub 2012 Jan 25.

46.
47.

CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation.

Qui HZ, Hagymasi AT, Bandyopadhyay S, St Rose MC, Ramanarasimhaiah R, Ménoret A, Mittler RS, Gordon SM, Reiner SL, Vella AT, Adler AJ.

J Immunol. 2011 Oct 1;187(7):3555-64. doi: 10.4049/jimmunol.1101244. Epub 2011 Aug 31.

48.

Duration of antigen availability influences the expansion and memory differentiation of T cells.

Blair DA, Turner DL, Bose TO, Pham QM, Bouchard KR, Williams KJ, McAleer JP, Cauley LS, Vella AT, Lefrançois L.

J Immunol. 2011 Sep 1;187(5):2310-21. doi: 10.4049/jimmunol.1100363. Epub 2011 Jul 20.

49.

Selective PGE(2) suppression inhibits colon carcinogenesis and modifies local mucosal immunity.

Nakanishi M, Menoret A, Tanaka T, Miyamoto S, Montrose DC, Vella AT, Rosenberg DW.

Cancer Prev Res (Phila). 2011 Aug;4(8):1198-208. doi: 10.1158/1940-6207.CAPR-11-0188. Epub 2011 May 16.

50.

The WSX-1 pathway restrains intestinal T-cell immunity.

McAleer JP, Saris CJ, Vella AT.

Int Immunol. 2011 Feb;23(2):129-37. doi: 10.1093/intimm/dxq464. Epub 2011 Jan 13.

Supplemental Content

Loading ...
Support Center